The Italian competition regulator was right to consider a drug licensed to treat eye conditions such as glaucoma and macular degeneration (Lucentis) and another to treat tumours (Avastin) as competing, the European Court of Justice has ruled.
We are seeing a rise in the number of complaints and claims arising from pupil references. Do schools have to provide references? What does your school risk if you get it wrong? We share some guidance to deal with these.
In August last year, Professor Sir John Bell unveiled industry-led proposals to build the UK’s status as a world leader in life sciences. The strategy was independent of the Government, so the Government was not bound by it...
Where an employee has received permanent health insurance payments, having opted to receive increased cover under a flexi-benefit scheme, employers may not be able to use these to offset compensation due to the employee.